The Data
/
Stocks
/ ELAN
Equity · Healthcare
ELAN
NYSE
Elanco Animal Health Incorporated
$22.92
+1.73% vs prior close
Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 9, 2026
1D
1M
3M
1Y
5Y
All
Price · Chart
58 sessions
The line runs $25.43 on 21 July through $22.92 on 9 October, on a scale from $20 to $28. Days the market did not trade hold the previous close, flat.
Interactive ELAN price chart by TradingView (requires JavaScript).
Market cap
$11.5B
52-week range
$19.81 – $26.83
Avg volume
452.9K
as of Oct 9, 2026
About Elanco Animal Health Incorporated
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Wikipedia · CC BY-SA 4.0
Company
Founded
1954
Headquarters
Greenfield
Exchange
NYSE
Sector
Healthcare
Class
Equity
Insiders Form 4
Filings 5 sets
ELAN insider trades
SEC Form 4 · last 90 days · newest reported trade 20 Aug 2026
Open-market buys
5
Open-market sells
0
Net bought
$1.47M
Non-trade filings
0
Date
Insider
Type
Shares
Value
20 Aug 2026
Kurzius Lawrence Erik
Director
Buy
40,000
$936K
18 Aug 2026
O'Neill Shiv
GC AND CORP SEC
Buy
3,998
$94K
12 Aug 2026
Harrington Michael J
Director
Buy
5,000
$109K
07 Aug 2026
Herendeen Paul
Director
Buy
10,000
$237K
07 Aug 2026
VanHimbergen Robert M
EVP and CFO
Buy
4,200
$97K
ELAN reported financials
SEC EDGAR XBRL
SEC EDGAR
ELAN reported revenue of $4.7B for the fiscal year ended 31 Dec 2025. Net income over the same period was −$232.0M.
Figure
Reported
Period
Revenue
$4.7B
31 Dec 2025
fiscal year
Net income
−$232.0M
31 Dec 2025
fiscal year
Diluted EPS
−$0.47
31 Dec 2025
fiscal year
Total assets
$13.6B
30 Jun 2026
at period end
Total equity
$6.6B
30 Jun 2026
at period end
ELAN earnings
SEC EDGAR
Date
Period
EPS
Revenue
30 Jun 2026
Q2 2026
$0.11
$1.37B
31 Mar 2026
Q1 2026
$0.11
$1.37B
31 Dec 2025
FY 2025
−$0.47
$4.72B
30 Sep 2025
Q3 2025
−$0.07
$1.14B
30 Jun 2025
Q2 2025
$0.02
$1.24B
31 Mar 2025
Q1 2025
$0.13
$1.19B
31 Dec 2024
FY 2024
$0.68
$4.44B
30 Sep 2024
Q3 2024
$0.73
$1.03B
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
10 of the 45 institutional funds we track reported a ELAN position for the quarter ended 30 Jun 2026 — a combined $435.2M; the latest of those filings landed 02 Sep 2026.
ELAN fails-to-deliver
SEC CNS data
SEC
On 29 Sep 2026, 3,913 shares of ELAN failed to deliver (about $88K).
Settlement date
Shares failed
Notional
% of shares out
29 Sep 2026
3,913
$88K
0.001%
17 Sep 2026
113
$3K
<0.001%
16 Sep 2026
40
$920
<0.001%
15 Sep 2026
369
$9K
<0.001%
09 Sep 2026
146
$3K
<0.001%
08 Sep 2026
80,345
$2.0M
0.016%
The most recent congressional trade disclosed in ELAN is a sale by Val T. Hoyle (house, OR), dated 23 Sep 2025.
Date
Member
Type
Amount
23 Sep 2025
filed 10 Oct 2025
Val T. Hoyle
house · Democrat–OR
Sale
$1K–$15K
06 Mar 2023
filed 17 Apr 2023
Daniel S. Goldman
house · Democrat–NY
Sale
$1K–$15K
30 Nov 2022
filed 29 Dec 2022
Susie Lee
house · Democrat–NV
Sale
$1K–$15K
10 Jun 2021
filed 13 Jul 2021
Susie Lee
house · Democrat–NV
Purchase
$1K–$15K
06 Nov 2020
filed 08 Dec 2020
Susie Lee
house · Democrat–NV
Sale
$1K–$15K
Sources
Finazon prior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
TradingView the price chart widget, drawn by TradingView from their own data
SEC EDGAR SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
SEC EDGAR SEC EDGAR 13F filings
SEC SEC fails-to-deliver (CNS) data
House disclosures U.S. House of Representatives financial disclosures
SEC EDGAR Valuation computed from SEC EDGAR filings
Wikipedia text of the lead paragraph, licensed CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) — https://en.wikipedia.org/wiki/Elanco